An amylin analog used as a challenge test for Alzheimer's disease. Academic Article uri icon

Overview

abstract

  • INTRODUCTION: Preclinical studies demonstrate the potential of amylin in the diagnosis of Alzheimer's disease (AD). We aimed to lay the foundation for repurposing the amylin analog and a diabetes drug, pramlintide, for AD in humans. METHODS: We administered a single subcutaneous injection of 60 μg of pramlintide to nondiabetic subjects under fasting conditions. RESULTS: None of the participants developed hypoglycemia after the injection of pramlintide. The pramlintide challenge induced a significant surge of amyloid-β peptide and a decrease in total tau in the plasma of AD subjects but not in control participants. The pramlintide injection provoked an increase in interleukin 1 receptor antagonist and a decrease in retinol-binding protein 4, which separates AD subjects from control subjects. DISCUSSION: Pramlintide use appeared to be safe in the absence of diabetes. The biomarker changes as a result of the pramlintide challenge, which distinguished AD from control subjects and mild cognitive impairment.

publication date

  • January 1, 2017

Identity

PubMed Central ID

  • PMC5424531

Scopus Document Identifier

  • 85012247300

Digital Object Identifier (DOI)

  • 10.1016/j.trci.2016.12.002

PubMed ID

  • 28503657

Additional Document Info

volume

  • 3

issue

  • 1